(Q42546418)

2 November 2017

Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. The Zafirlukast Trialists Group (English)

1 reference

multicenter clinical trial

2 November 2017

0 references

0 references

1 reference

J E Fish

1

1 reference

2 November 2017

J P Kemp

2

1 reference

2 November 2017

R F Lockey

3

1 reference

2 November 2017

M Glass

4

1 reference

2 November 2017

L A Hanby

5

1 reference

2 November 2017

C M Bonuccelli

6

1 reference

2 November 2017

1 July 1997

1 reference

2 November 2017

Clinical Therapeutics

1 reference

2 November 2017

19

1 reference

2 November 2017

4

1 reference

2 November 2017

675-690

1 reference

Mucosal inflammation in asthma

2 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980092-6

7 January 2021

Expression of mRNA for interleukin-5 in mucosal bronchial biopsies from asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980092-6

7 January 2021

Cytokines in symptomatic asthma airways

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980092-6

7 January 2021

Generation and metabolism of 5-lipoxygenase pathway leukotrienes by human eosinophils: predominant production of leukotriene C4.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980092-6

7 January 2021

Leukotrienes, LTC4 and LTB4, in bronchoalveolar lavage in bronchial asthma and other respiratory diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980092-6

7 January 2021

Role of inflammatory mediators in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980092-6

7 January 2021

Urinary Excretion of Leukotriene E4and 11-dehydro-Thromboxane B2in Response to Bronchial Provocations with Allergen, Aspirin, Leukotriene D4, and Histamine in Asthmatics

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980092-6

7 January 2021

Recovery of Leukotriene E4from the Urine of Patients with Airway Obstruction

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980092-6

7 January 2021

Urinary leukotriene E4 after antigen challenge and in acute asthma and allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980092-6

7 January 2021

Urinary Leukotriene E4Concentrations Increase after Aspirin Challenge in Aspirin-sensitive Asthmatic Subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980092-6

7 January 2021

Role of leukotrienes in exercise-induced asthma. Inhibitory effect of ICI 204219, a potent leukotriene D4 receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980092-6

7 January 2021

The leukotriene-antagonist ICI-204,219 inhibits the early airway reaction to cumulative bronchial challenge with allergen in atopic asthmatics

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980092-6

7 January 2021

Effect of the oral leukotriene antagonist, ICI 204,219, on antigen-induced bronchoconstriction in subjects with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980092-6

7 January 2021

Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980092-6

7 January 2021

Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980092-6

7 January 2021

Measuring quality of life in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980092-6

7 January 2021

10.1016/S0149-2918(97)80092-6

Identifiers

DOI

1 reference

2 November 2017

1 reference